Henry Schein, Inc. has entered into a new exclusive distribution agreement with CytoChip Inc. for its product, the CitoCBC®? system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care.
The CitoCBC system delivers full CBC results in approximately eight minutes, requires minimal staff training, and provides lab-quality accuracy by miniaturizing advanced fluorescent flow cytometry technology onto a cartridge for use in near-patient settings. Henry Schein's exclusivity in the United States includes ambulatory care settings such as physician offices, urgent care centers, as well as critical access hospitals with 25 patient beds or fewer. The exclusivity does not include long-term care or acute care facilities.
Henry Schein, Inc. specializes in the distribution of care products and services intended for health professionals (doctors, surgeons, dentists, veterinary laboratories and clinics). Net sales break down by activity as follows:
- distribution of health care products and equipment (83.8%): dental products and equipment (62.1% of net sales; consumable products, laboratory equipment, print materials, implants, anesthetics, etc.) and medical equipment (37.9%; medicines, vaccines, vitamins, surgical material, diagnostic tests, etc.);
- other (16.2%): sale and integration of management software, financial, training, maintenance and equipment repair services.
The United States account for 69.5% of net sales.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
